Virology An antiviral that combines Rebetol®–ribavirin and Intron® A–recombinant IFN alfa-2b injection for treating chronic HCV in Pts with compensated liver disease. See Hepatitis C virus, Interferon.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C.
veterans' experience with rebetron in a nonstudy environment: success or failure?
* Interferons such as Roferon-A, Intron-A, and Rebetron, used to boost immune response
He successfully completed a course of rebetron and ribavirin and was cleared for renal transplant.
Schering-Plough's United States alpha interferon products include INTRON A (interferon alfa-2b, recombinant) Injection; PEG-INTRON (peginterferon alfa-2b) Powder for Injection; and REBETRON Combination Therapy containing REBETOL (ribavirin, USP) Capsules and INTRON A.
"These earnings reflect the successful launch of the new combination of PEG-Intron-Rebetol in the US and Europe and the launch of Rebetron combination treatment in Japan by our partner, Schering-Plough," said Johnson Y.N.
The FDA encourages health care providers to report pregnancies in women on Rebetol or the sexual partners of men on Rebetol to the Rebetron Pregnancy Registry at 800-727-7064.
Schering-Plough has reported it will continue to market REBETRON Combination Therapy in the United States.
Fried, MD, of the University of North Carolina, Chapel Hill, and colleagues found a higher sustained viral response rate among HCV patients treated with this combination of drugs than with the current standard therapy, interferon alfa-2b plus ribavirin (Rebetron), said a Medscape Wire article.
Hepatitis C has no cure and no vaccine to combat it, but a new product, Rebetron, received FDA approval last June for the treatment of chronic hepatitis C in patients who have undergone a relapse following alpha interferon therapy.
Schering-Plough Corporation, Madison, NJ, announced the US Food and Drug Administration (FDA) has approved Rebetron Combination Therapy containing Rebetol (ribavirin, USP) capsules and Intron A (interferon alfa-2b, recombinant) injection for the treatment of hepatitis C in patients with compensated liver disease previously untreated with alpha interferon therapy.
Ribavirin, a nucleoside analogue, is licensed to Schering-Plough (Kenilworth, NJ) and marketed in combination with Schering-Plough's interferon alfa-2b product (Rebetron) and with pegylated interferon alfa-2b (PEG-Intron -- Rebetol) for the treatment of chronic hepatitis C.